Analysis of cardiotoxicity of recombinant human endostatin combined with chemotherapy

Chinese Journal of Clinical Oncology

Volumn 35, Issue 1, 2008, Pages 12-14

  Qin, Jing ^a   Zhang, Penghai ^a   Qian, Xinyu ^a   Li, Aimin ^a   Luo, Rongcheng ^a   Xu, Dingli ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Markers of early detection; Recombinant human endostatin

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOSTATIN; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; TREATMENT RESPONSE;

EID: 67650533418     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management [J].Circulation, 2004, 109(25):3122-3131
2. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88 (2): 277-285 (Pubitemid 28015876)
3. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition [J]. Nat Rev Cancer, 2007, 7(5): 332-344 (Pubitemid 46652481)
4. Bengala C, Zamagni C, Pedrazzoli P, et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study [J]. Br J Cancer, 2006, 94(7): 1016-1020
5. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab[J]. J Clin Oncol, 2004, 22 (2): 322-329
6. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment [J]. J Clin Oncol, 2005, 23(31): 7820-7826
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792 (Pubitemid 32222155)
8. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience[J]. J Clin Oncol, 2002, 20(5): 1215-1221 (Pubitemid 34177427)
9. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate [J]. Nat Med, 2006, 12 (8): 908-916 (Pubitemid 44175142)